406 related articles for article (PubMed ID: 30202085)
21. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies.
Piha-Paul SA; Oh DY; Ueno M; Malka D; Chung HC; Nagrial A; Kelley RK; Ros W; Italiano A; Nakagawa K; Rugo HS; de Braud F; Varga AI; Hansen A; Wang H; Krishnan S; Norwood KG; Doi T
Int J Cancer; 2020 Oct; 147(8):2190-2198. PubMed ID: 32359091
[TBL] [Abstract][Full Text] [Related]
22. Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006.
Long GV; Arance A; Mortier L; Lorigan P; Blank C; Mohr P; Schachter J; Grob JJ; Lotem M; Middleton MR; Neyns B; Steven N; Ribas A; Walpole E; Carlino MS; Lebbe C; Sznol M; Jensen E; Leiby MA; Ibrahim N; Robert C
Ann Oncol; 2022 Feb; 33(2):204-215. PubMed ID: 34710571
[TBL] [Abstract][Full Text] [Related]
23. Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma.
Robert C; Carlino MS; McNeil C; Ribas A; Grob JJ; Schachter J; Nyakas M; Kee D; Petrella TM; Blaustein A; Lotem M; Arance A; Daud AI; Hamid O; Larkin J; Anderson J; Krepler C; Grebennik D; Long GV
J Clin Oncol; 2023 Aug; 41(24):3998-4003. PubMed ID: 37348035
[No Abstract] [Full Text] [Related]
24. Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041).
Yamazaki N; Takenouchi T; Fujimoto M; Ihn H; Uchi H; Inozume T; Kiyohara Y; Uhara H; Nakagawa K; Furukawa H; Wada H; Noguchi K; Shimamoto T; Yokota K
Cancer Chemother Pharmacol; 2017 Apr; 79(4):651-660. PubMed ID: 28283736
[TBL] [Abstract][Full Text] [Related]
25. Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules.
Long GV; Robert C; Butler MO; Couture F; Carlino MS; O'Day S; Atkinson V; Cebon JS; Brown MP; Dalle S; Hill AG; Gibney GT; McCune S; Menzies AM; Niu C; Ibrahim N; Moreno BH; Diab A
Clin Cancer Res; 2021 Oct; 27(19):5280-5288. PubMed ID: 34210681
[TBL] [Abstract][Full Text] [Related]
26. Retrospective analysis of treatment-naive Slovenian patients with metastatic melanoma treated with pembrolizumab - real-world experience.
Hribernik N; Boc M; Ocvirk J; Knez-Arbeiter J; Mesti T; Ignjatovic M; Rebersek M
Radiol Oncol; 2020 Jan; 54(1):119-127. PubMed ID: 31955148
[TBL] [Abstract][Full Text] [Related]
27. Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study.
Hansen AR; Massard C; Ott PA; Haas NB; Lopez JS; Ejadi S; Wallmark JM; Keam B; Delord JP; Aggarwal R; Gould M; Yang P; Keefe SM; Piha-Paul SA
Ann Oncol; 2018 Aug; 29(8):1807-1813. PubMed ID: 29992241
[TBL] [Abstract][Full Text] [Related]
28. Pembrolizumab Utilization and Outcomes for Advanced Melanoma in US Community Oncology Practices.
Cowey CL; Liu FX; Black-Shinn J; Stevinson K; Boyd M; Frytak JR; Ebbinghaus SW
J Immunother; 2018; 41(2):86-95. PubMed ID: 29252916
[TBL] [Abstract][Full Text] [Related]
29. A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation.
Lala M; Li TR; de Alwis DP; Sinha V; Mayawala K; Yamamoto N; Siu LL; Chartash E; Aboshady H; Jain L
Eur J Cancer; 2020 May; 131():68-75. PubMed ID: 32305010
[TBL] [Abstract][Full Text] [Related]
30. Pembrolizumab: A Review in Advanced Melanoma.
Deeks ED
Drugs; 2016 Mar; 76(3):375-86. PubMed ID: 26846323
[TBL] [Abstract][Full Text] [Related]
31. Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006.
Hamid O; Robert C; Daud A; Carlino MS; Mitchell TC; Hersey P; Schachter J; Long GV; Hodi FS; Wolchok JD; Arance A; Grob JJ; Joshua AM; Weber JS; Mortier L; Jensen E; Diede SJ; Moreno BH; Ribas A
Eur J Cancer; 2021 Nov; 157():391-402. PubMed ID: 34571336
[TBL] [Abstract][Full Text] [Related]
32. Metastatic melanoma: pretreatment contrast-enhanced CT texture parameters as predictive biomarkers of survival in patients treated with pembrolizumab.
Durot C; Mulé S; Soyer P; Marchal A; Grange F; Hoeffel C
Eur Radiol; 2019 Jun; 29(6):3183-3191. PubMed ID: 30645669
[TBL] [Abstract][Full Text] [Related]
33. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.
Shaverdian N; Lisberg AE; Bornazyan K; Veruttipong D; Goldman JW; Formenti SC; Garon EB; Lee P
Lancet Oncol; 2017 Jul; 18(7):895-903. PubMed ID: 28551359
[TBL] [Abstract][Full Text] [Related]
34. FDA Approval Summary: Pembrolizumab for the Treatment of Patients with Unresectable or Metastatic Melanoma.
Barone A; Hazarika M; Theoret MR; Mishra-Kalyani P; Chen H; He K; Sridhara R; Subramaniam S; Pfuma E; Wang Y; Li H; Zhao H; Zirkelbach JF; Keegan P; Pazdur R
Clin Cancer Res; 2017 Oct; 23(19):5661-5665. PubMed ID: 28179454
[TBL] [Abstract][Full Text] [Related]
35. Ipilimumab Real-World Efficacy and Safety in Korean Melanoma Patients from the Korean Named-Patient Program Cohort.
Jung M; Lee J; Kim TM; Lee DH; Kang JH; Oh SY; Lee SJ; Shin SJ
Cancer Res Treat; 2017 Jan; 49(1):44-53. PubMed ID: 27121719
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab.
Hodi FS; Hwu WJ; Kefford R; Weber JS; Daud A; Hamid O; Patnaik A; Ribas A; Robert C; Gangadhar TC; Joshua AM; Hersey P; Dronca R; Joseph R; Hille D; Xue D; Li XN; Kang SP; Ebbinghaus S; Perrone A; Wolchok JD
J Clin Oncol; 2016 May; 34(13):1510-7. PubMed ID: 26951310
[TBL] [Abstract][Full Text] [Related]
37. Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer.
Chatterjee M; Turner DC; Felip E; Lena H; Cappuzzo F; Horn L; Garon EB; Hui R; Arkenau HT; Gubens MA; Hellmann MD; Dong D; Li C; Mayawala K; Freshwater T; Ahamadi M; Stone J; Lubiniecki GM; Zhang J; Im E; De Alwis DP; Kondic AG; Fløtten Ø
Ann Oncol; 2016 Jul; 27(7):1291-8. PubMed ID: 27117531
[TBL] [Abstract][Full Text] [Related]
38. Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study.
Hsu C; Lee SH; Ejadi S; Even C; Cohen RB; Le Tourneau C; Mehnert JM; Algazi A; van Brummelen EMJ; Saraf S; Thanigaimani P; Cheng JD; Hansen AR
J Clin Oncol; 2017 Dec; 35(36):4050-4056. PubMed ID: 28837405
[TBL] [Abstract][Full Text] [Related]
39. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies.
Algazi AP; Tsai KK; Shoushtari AN; Munhoz RR; Eroglu Z; Piulats JM; Ott PA; Johnson DB; Hwang J; Daud AI; Sosman JA; Carvajal RD; Chmielowski B; Postow MA; Weber JS; Sullivan RJ
Cancer; 2016 Nov; 122(21):3344-3353. PubMed ID: 27533448
[TBL] [Abstract][Full Text] [Related]
40. Japanese real-world study of sequential nivolumab and ipilimumab treament in melanoma.
Tsutsumida A; Fukushima S; Yokota K; Yoshikawa S; Yamasaki O; Tanemura A; Okuyama R; Uhara H; Muto Y; Miyashita A; Akiyama M; Kaji T; Koga H; Kato J; Katayama T; Itakura E; Yamazaki N; Kiyohara Y
J Dermatol; 2019 Nov; 46(11):947-955. PubMed ID: 31531895
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
